On November 2, 2018 Cerus Corporation (Nasdaq:CERS) reported that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin Green, Cerus’ vice president, finance and chief financial officer, are scheduled to present a corporate update at the 2018 Stephens NY Investment Conference at 9:45 a.m. ET on Thursday, November 8, 2018 (Press release, Cerus, NOV 2, 2018, View Source [SID1234530616]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at View Source A replay will be available for approximately two weeks following the completion of the event.

On November 2, 2018 Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, reported an upcoming poster presentation at the 2018 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, taking place from December 1-4, 2018 in San Diego, CA (Press release, Bio-Path Holdings, NOV 2, 2018, View Source [SID1234530611]). In addition, ASH (Free ASH Whitepaper) abstracts will appear in the November supplemental issue of Blood.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Maro Ohanian, Assistant Professor of the Department of Leukemia at The University of Texas M.D. Anderson Cancer Center, will present interim data from the ongoing Phase 2 trial of prexigebersen (BP1001), the Company’s lead drug candidate, for the treatment of acute myeloid leukemia. Co-author Dr. Ana Tari Ashizawa, Vice President of Research and Development at Bio-Path, will also be available at the poster presentation

Details for the presentation are as follows:

Date: Saturday, December 1, 2018

Presentation Time: 6:15 PM – 8:15 PM Pacific Time

Location: San Diego Convention Center, Hall GH

Session Name: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I

Title: Interim Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with Untreated Acute Myeloid Leukemia (AML)

On November 2, 2018 Celgene Corporation (NASDAQ:CELG) reported to present at two upcoming investor events where Celgene management will provide an overview of the Company (Press release, Celgene, NOV 2, 2018, View Source [SID1234530609]). The events will be webcast live and will be available in the Investor Relations section of the Company’s website at www.celgene.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wednesday, November 14, 2018, Celgene will present at the Credit Suisse 27th Annual Healthcare Conference at 9:45 am MST/ 11:45 am ET

Sunday, December 2, 2018, Celgene will host an Analyst & Investor Event at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting at 8:00 pm PT/ 11:00 pm ET

On November 2, 2018 Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that data derived from its JTX-2011 program will be presented in two poster sessions at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 33rd Annual Meeting, being held November 9-11, 2018 in Washington, D.C (Press release, Jounce Therapeutics, NOV 2, 2018, View Source;p=RssLanding&cat=news&id=2375150 [SID1234530608]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Details:

Poster Title: Emergence of an ICOS hi CD4 T cell subset correlates with tumor reductions in subjects treated with the ICOS agonist antibody JTX-2011
Author: Christopher Harvey Ph.D., Jounce Therapeutics, Inc.
Session: Biomarkers and Immune Monitoring
Poster Session Number: 52
Location: Hall E
Date and Time: Saturday, November 10, 2018; 12:20pm–1:50pm ET and 7:00pm–8:30pm ET

Poster Title: Inducible T cell Co-stimulator (ICOS) is upregulated on lymphocytes following radiation of tumors and ICOS agonism in combination with radiation results in enhanced tumor control
Author: Michael J. Gough Ph.D., Earle A. Chile’s Research Institute, Providence Portland Medical Center, Portland Oregon
Session: Immune Effects of Chemotherapy, Radiation and Targeted Therapies
Poster Session Number: 455
Location: Hall E
Date and Time: Friday, November 9, 2018; 12:45pm–2:15pm ET and 6:30pm–8pm ET

About JTX-2011
Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells. Preclinical data support that JTX-2011 may have a dual mechanism of action that stimulates anti-tumor T effector cells, and also reduces the immunosuppressive T regulatory cells in the tumor microenvironment. The company is developing JTX-2011 to treat solid tumors as a single agent and in combination with other therapies.

On November 2, 2018 BerGenBio ASA (OSE:BGBIO) reported that the analysis of the first stage of its Phase II clinical trial with bemcentinib, a first-in-class selective oral AXL inhibitor, in combination with the anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with previously treated, advanced non-small cell lung cancer (NSCLC) has been selected as a Late-breaking Abstract at the annual Society for Immunotherapy in Cancer (SITC) (Free SITC Whitepaper) 2018 congress in Washington D.C. (7-10 November 2018) (Press release, BerGenBio, NOV 2, 2018, View Source [SID1234530606]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Late-breaking abstracts highlight novel and potentially practice-changing studies, and their acceptance for presentation is subject to favourable assessment by a panel of clinical and scientific experts. In total, only 21 abstracts were accepted in the late-breaking category at this year’s SITC (Free SITC Whitepaper) congress: View Source

An update from BerGenBio’s biomarker and companion diagnostic programme will also be presented as a poster within the regular abstract section. See details below.

Presentations at SITC (Free SITC Whitepaper):
Friday 9 November, 12:45 – 2:15 p.m. and 6:30 – 8 p.m. EST, Hall E

A Phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Analysis of the first stage
Matthew Krebs, PhD, et al
Category: 33rd Annual Meeting Late-Breaking Abstracts
Presentation number: P715

Predictive and pharmacodynamic biomarkers associated with treatment with the oral selective AXL Inhibitor bemcentinib in combination with pembrolizumab in patients with advanced NSCLC and Melanoma
Robert Holt, PhD, et al
Category: Biomarkers and Immune Monitoring
Presentation number: P115
The full abstracts will be published on November 6th at 8 a.m. Eastern time at View Source

About SITC (Free SITC Whitepaper)
The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) is the world’s leading member-driven organisation specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Over 4,000 delegates are expected to attend the SITC (Free SITC Whitepaper) 33rd Annual Congress in Washington D.C. on Nov 7-10 2018. For more information please see www.sitcancer.org